Posted by Michael Wonder on 27 Apr 2022
Pfizer and Biohaven's Vydura (rimegapant) granted first ever marketing authorisation by European Commission for both acute treatment of migraine and prophylaxis of episodic migraine
27 April 2022 - Pfizer and Biohaven Pharmaceutical today announced that the European Commission has granted marketing authorisation for Vydura (rimegepant), a calcitonin gene-related peptide receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month.
Vydura, an orally disintegrating tablet, is the first medicine approved for both acute and prophylactic treatment of migraine in the European Union.
